Mineralys Therapeutics, Inc. (MLYS) Stock Price & Analysis
Mineralys Therapeutics, Inc. (MLYS) rose 7.47% to USD 24.18 as of June 10, 2026 at 00:53 UTC, according to Nexqual real-time market data.
MLYS last closed at USD 22.5; the session ranged USD 22.86–24.25 on volume of 2,549,003 shares. Market capitalization is $2.13B, with a 52-week range of USD 12.59–47.65 (NMS). Source: Nexqual, June 10, 2026 at 00:53 UTC.
Key Statistics (as of June 10, 2026 at 00:53 UTC)
| Price | USD 24.18 |
|---|---|
| Change | ▲ 7.47% (up) |
| Previous Close | USD 22.5 |
| Open | USD 22.89 |
| Day Range | USD 22.86 – 24.25 |
| 52-Week Range | USD 12.59 – 47.65 |
| Volume | 2,549,003 shares |
| Market Cap | $2.13B |
| Exchange | NMS |
Technical Analysis (MLYS)
Nexqual's technical model rates MLYS "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.75 (neutral) |
| vs SMA50 | Below (USD 27.98) |
| MACD | -1 (negative) |
Analyst Ratings (MLYS)
Wall Street analysts rate MLYS "Strong Buy" based on 8 analysts, with a mean price target of USD 49 (range USD 30–56), per Nexqual as of June 10, 2026 at 00:53 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 49 |
| High Target | USD 56 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (MLYS)
| Next Earnings Date | 2026-05-06 |
|---|---|
| EPS Estimate | USD -0.54 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.47 vs est -0.44 ▼ miss |
| 2025-12-31 | USD -0.4 vs est -0.52 ▲ beat |
| 2025-09-30 | USD -0.52 vs est -0.61 ▲ beat |
| 2025-06-30 | USD -0.66 vs est -0.74 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financials & Fundamentals (MLYS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -30.99% |
| Current Ratio | 44.33 |
| Total Cash | $646.06M |
| Total Debt | $0 |
| Free Cash Flow | $-78.52M |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financial Health Score (MLYS)
Nexqual rates Mineralys Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $646M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$136M |
| Efficiency | Critical — ROE -31%, ROA -21.3% |
Ownership (MLYS)
| Insider Ownership | +0.67% |
|---|---|
| Institutional Ownership | +109.39% |
| Shares Outstanding | 88.16M |
| Float | 60.37M |
| Short % of Float | +13.28% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Leadership (MLYS)
Mineralys Therapeutics, Inc. is led by Jon Congleton (age 62), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:53 UTC.
| President, CEO & Director | Jon Congleton (age 62) |
|---|---|
| Founder & Executive Director | Brian Taylor Slingsby M.D., M.P.H. (age 48) |
| CFO & Secretary | Adam Scott Levy (age 47) |
| Senior Vice President of CMC | Robert McKean |
| Senior Vice President of Quality Assurance | Danielle Mahoney |
Major Backers & Investors (MLYS)
Notable institutional backers of Mineralys Therapeutics, Inc. include Catalys Pacific, LLC, RA Capital Management, L.P., Samsara BioCapital, LLC, according to Nexqual as of June 10, 2026 at 00:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Catalys Pacific, LLC | 9.58% |
| RA Capital Management, L.P. | 9.32% |
| Samsara BioCapital, LLC | 7.12% |
| FMR, LLC | 5.89% |
| Wellington Management | 4.07% |
| Caligan Partners, LP | 3.36% |
| Fidelity | 2.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.35% |
| BlackRock | 6.79% |
| State Street | 5.96% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
From Mineralys Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our granted patents may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates.
- Drug Development Process In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (FDCA), the Public Health Service (PHS) Act, and implementing regulations.
- Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.
- As of February 26, 2026, our patent portfolio comprises 16 distinct patent families protecting our technology relating to lorundrostat and its synthetic intermediates, methods of synthesizing lorundrostat and related compounds, various formulations of lorundrostat products, as well as methods of treating diseases with lorundrostat and related compounds.
Partnerships
- We have remaining obligations to pay Tanabe commercial milestone payments of up to $155.0 million in the aggregate upon first commercial sale and upon meeting certain annual sales targets, as well as additional commercial milestone payments of up to $10.0 million for a second indication.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | USD 10.45 | ▲ 1.36% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| ELVN | Enliven Therapeutics, Inc. | USD 36.11 | ▲ 4.03% |
| APGE | Apogee Therapeutics, Inc. | USD 85 | ▼ 2.21% |
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:53 UTC. This page is informational and not investment advice.